Axovant reports Phase II data for dementia candidate nelotanserin

Axovant Sciences Ltd. (NASDAQ:AXON) reported data from 27 evaluable patients with dementia with Lewy bodies (DLB) and Parkinson's disease dementia who were experiencing frequent and recurrent visual hallucinations in a

Read the full 306 word article

User Sign In